News

If approved, this will become the fourth indication for Pradaxa (dabigatran etexilate mesylate). The sNDA is based on the results of two randomized, double-blind Phase III trials, RE-NOVATE

As part of the deal, Sanofi Pasteur will have an option to acquire certain worldwide rights to use VBI’s LPV technology in its vaccines to provide improved stability.

Data from this trial supported the initiation of the ongoing, pivotal Phase II METRIC trial in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab

FOLFIRI is an irinotecan-based chemotherapy regimen, which is frequently used in first-line colorectal cancer treatment in Europe. The approval from the new indication is based on data from

The deal will give BMS exclusive access to uniQure’s gene therapy technology platform for the development of new treatments. The companies will collaborate on up to ten targets,

Demcizumab is a humanized monoclonal antibody that inhibits Delta-Like Ligand 4 (DLL4) in the Notch signaling pathway. Under the deal, OncoMed’s demcizumab will be tested in combination with

BIND is focused on developing targeted and programmable therapeutics called Accurins. The deal was originally established in April 2013 and the timeline for Pfizer to exercise its option

Under the deal, Schrödinger could receive up to $120m, which includes preclinical milestones. Computer aided design (CAD) plays a major role in nearly all industries ranging from airplane

Nucynta is indicated to manage moderate-to-severe acute pain in adults, Nucynta ER extended release tablets are indicated to manage pain, including neuropathic pain associated with diabetic peripheral neuropathy